<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00350961</url>
  </required_header>
  <id_info>
    <org_study_id>GEMOXEL cholangiocarcinoma</org_study_id>
    <nct_id>NCT00350961</nct_id>
  </id_info>
  <brief_title>Gemcitabine, Oxaliplatin and Capecitabine in Patients With Advanced Cholangiocarcinoma</brief_title>
  <official_title>Phase I-II Study of bi-Weekly Fixed Dose Rate Gemcitabine, Oxaliplatin and Capecitabine in Patients With Advanced Cholangiocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Henrik Jensen, Dept. of Oncology, Vejle Sygehus, Vejle, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <brief_summary>
    <textblock>
      In Denmark approximately 200 new cases of cholangiocarcinoma are diagnosed every year. No&#xD;
      standard treatment exists for patients with advanced cholangiocarcinoma, and improved&#xD;
      systemic treatments are needed.&#xD;
&#xD;
      Duplets of gemcitabine, oxaliplatin and capecitabine have been evaluated in various cancers&#xD;
      and several different regimens are well tolerated and active, especially in upper&#xD;
      gastrointestinal cancers, exocrine pancreatic cancer and non-small cell lung cancer.&#xD;
&#xD;
      The triplet combination of these agents has not been studied, but a triplet combination of&#xD;
      gemcitabine, oxaliplatin and 5-FU infusion has been evaluated in a phase I study.&#xD;
&#xD;
      Bi-weekly combination of gemcitabine and oxaliplatin has proven active and tolerable and&#xD;
      warrants further study. In addition, fixed dose rate infusion of gemcitabine has shown&#xD;
      interesting as the ability of mononuclear cells to accumulate gemcitabine triphosphate during&#xD;
      therapy seems to be saturable.&#xD;
&#xD;
      We propose a phase I-II study of a bi-weekly schedule of gemcitabine, oxaliplatin and&#xD;
      capecitabine. This regimen could be feasible in an out-patients setting.&#xD;
&#xD;
      The phase I part is a standard dose escalation study for patients with solid tumors. In the&#xD;
      phase II part the recommended dose is studied in patients with advanced cholangiocarcinoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Design&#xD;
&#xD;
      Open, non-randomized phase I/II study.&#xD;
&#xD;
      Purpose:&#xD;
&#xD;
      Phase I part To find MTD and RFTD for the combination of gemcitabine, oxaliplatin and&#xD;
      capecitabine.&#xD;
&#xD;
      Dose Escalating Schedule Dose level Dose Gemcitabine 10 mg/m2/min 600-1000 mg/m2 day 1 and 14&#xD;
      Capecitabine p.o. x 2 daily. 1000-1250 mg/m2 day 1-7 and 14-21 Oxaliplatin 60-80 mg/m2day 1&#xD;
      and 14 Drugs: G C O Level 1 600 1000 60 Level 2 800 1000 60 Level 3 1000 1000 60 Level 4 1000&#xD;
      1250 60 Level 5 1000 1250 80 Level 6 1200 1250 80 Start level: Level 1, 3 patients per level&#xD;
&#xD;
      Phase II part The primary endpoint is the objective response rate The secondary endpoint is&#xD;
      toxicity, response duration and time to progression.&#xD;
&#xD;
      Treatment:&#xD;
&#xD;
      Gemcitabine Gemcitabine is given intravenously on day 1 and 14 with a fixed dose rate of 10&#xD;
      mg/m2/min.&#xD;
&#xD;
      Oxaliplatin Oxaliplatin is given intravenously on day 1 and 14 as a 2 hours infusion.&#xD;
&#xD;
      Capecitabine Capecitabine is given orally and administered in tablets of 150 mg and 500 mg.&#xD;
      The dose is administered twice daily with 12 hours interval, in the morning and evening&#xD;
      during or latest 30 minutes after a meal.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2004</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SUrvival</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">39</enrollment>
  <condition>Cholangiocarcinoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically proven intra- or extrahepatic cholangiocarcinoma, papilla of the Vater&#xD;
             or gallbladder carcinoma.&#xD;
&#xD;
          -  PS 0-2&#xD;
&#xD;
          -  Age 18-75&#xD;
&#xD;
          -  Life expectancy &gt; 12 weeks&#xD;
&#xD;
          -  Normal bone marrow function (neutrophiles &gt; 1,5 x 109/l and platelets &gt; 100 x 109/l)&#xD;
&#xD;
          -  Bilirubin &lt; 1,5 x UNL&#xD;
&#xD;
          -  Transaminases &lt; 3 x UNL&#xD;
&#xD;
          -  Normal renal function, Cr-EDTA clearance &gt; 50 ml/min&#xD;
&#xD;
          -  No chemotherapy, radiotherapy or immunotherapy 4 weeks prior to inclusion&#xD;
&#xD;
          -  No known DPD-deficiency&#xD;
&#xD;
          -  No neuropathy&#xD;
&#xD;
          -  No uncontrolled, severe concurrent medical disease&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Chemotherapy, radiotherapy or immunotherapy 4 weeks prior to inclusion&#xD;
&#xD;
          -  Experimental therapy &lt; 8 weeks prior to inclusion&#xD;
&#xD;
          -  Uncontrolled, severe concurrent medical disease&#xD;
&#xD;
          -  Prior malignancy during the last 5 years, except for non-melanoma skin cancer and&#xD;
             carcinoma in situ cervix uteri.&#xD;
&#xD;
          -  Allergy to gemcitabine, oxaliplatin or capecitabine&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ulrik Lassen, MD., PH.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, Dept. of Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vejle Sygehus</name>
      <address>
        <city>Vejle</city>
        <zip>7100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>August 2008</verification_date>
  <study_first_submitted>July 10, 2006</study_first_submitted>
  <study_first_submitted_qc>July 10, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2006</study_first_posted>
  <last_update_submitted>August 25, 2008</last_update_submitted>
  <last_update_submitted_qc>August 25, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 26, 2008</last_update_posted>
  <keyword>Cholangiocarcinoma</keyword>
  <keyword>Fixed dose rate</keyword>
  <keyword>Gemcitabine</keyword>
  <keyword>Oxaliplatin</keyword>
  <keyword>Capecitabine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangiocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

